Alice N Hemenway1, Alexandra M Terry1. 1. College of Pharmacy, Rockford Regional Campus, The University of Illinois at Chicago, Rockford, IL, USA.
Abstract
Background: Several recent studies have shown that both lower doses and shorter durations of systemic corticosteroids have similar efficacy for treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). However, each trial has limitations that constrain direct applicability to a US hospital population. Objective: The aim of this study was to determine whether, in a US community hospital, low doses of corticosteroids provide the lowest risk of adverse effects without increasing length of stay or readmission rate. Methods: A single-center retrospective cohort was performed using patients meeting criteria for AECOPD. Primary endpoints included length of hospitalization, proportion of patients with >30% increase in blood glucose from baseline, and rate of 30-day readmission; multivariable regression analysis was used for comparison. The 3 inpatient cumulative dose range groups were low: ≤250-mg prednisone equivalents, medium: 251 to 500 mg, and high: ≥501 mg. Results: A total of 665 records were evaluated, with 369 records included. As the corticosteroid dose ranges increased, there were more patients with increased blood glucose (33.3%, 54.4%, 59.9%). When holding all other factors constant, there was a statistically significant increase in patients with elevated blood glucose with the medium- and high-dose groups as compared with the low-dose group (P < .009, P < .001), the average length of stay was 21.3 hours higher in the high-dose group as compared with the low-dose group (P < .001), and there were no significant differences in readmission rates between the dose groups. Conclusions: The lowest dose range of corticosteroids was associated with the lowest rate of impaired blood glucose without a statistically significant increase in length of stay or readmission rate.
Background: Several recent studies have shown that both lower doses and shorter durations of systemic corticosteroids have similar efficacy for treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). However, each trial has limitations that constrain direct applicability to a US hospital population. Objective: The aim of this study was to determine whether, in a US community hospital, low doses of corticosteroids provide the lowest risk of adverse effects without increasing length of stay or readmission rate. Methods: A single-center retrospective cohort was performed using patients meeting criteria for AECOPD. Primary endpoints included length of hospitalization, proportion of patients with >30% increase in blood glucose from baseline, and rate of 30-day readmission; multivariable regression analysis was used for comparison. The 3 inpatient cumulative dose range groups were low: ≤250-mg prednisone equivalents, medium: 251 to 500 mg, and high: ≥501 mg. Results: A total of 665 records were evaluated, with 369 records included. As the corticosteroid dose ranges increased, there were more patients with increased blood glucose (33.3%, 54.4%, 59.9%). When holding all other factors constant, there was a statistically significant increase in patients with elevated blood glucose with the medium- and high-dose groups as compared with the low-dose group (P < .009, P < .001), the average length of stay was 21.3 hours higher in the high-dose group as compared with the low-dose group (P < .001), and there were no significant differences in readmission rates between the dose groups. Conclusions: The lowest dose range of corticosteroids was associated with the lowest rate of impaired blood glucose without a statistically significant increase in length of stay or readmission rate.
Authors: Sammuel V Anderegg; Samaneh T Wilkinson; Rick J Couldry; Dennis W Grauer; Eric Howser Journal: Am J Health Syst Pharm Date: 2014-09-01 Impact factor: 2.637
Authors: Tyree H Kiser; Richard R Allen; Robert J Valuck; Marc Moss; R William Vandivier Journal: Am J Respir Crit Care Med Date: 2014-05-01 Impact factor: 21.405
Authors: David Meltzer; Willard G Manning; Jeanette Morrison; Manish N Shah; Lei Jin; Todd Guth; Wendy Levinson Journal: Ann Intern Med Date: 2002-12-03 Impact factor: 25.391
Authors: Carl van Walraven; Irfan A Dhalla; Chaim Bell; Edward Etchells; Ian G Stiell; Kelly Zarnke; Peter C Austin; Alan J Forster Journal: CMAJ Date: 2010-03-01 Impact factor: 8.262
Authors: Jörg D Leuppi; Philipp Schuetz; Roland Bingisser; Michael Bodmer; Matthias Briel; Tilman Drescher; Ursula Duerring; Christoph Henzen; Yolanda Leibbrandt; Sabrina Maier; David Miedinger; Beat Müller; Andreas Scherr; Christian Schindler; Rolf Stoeckli; Sebastien Viatte; Christophe von Garnier; Michael Tamm; Jonas Rutishauser Journal: JAMA Date: 2013-06-05 Impact factor: 56.272
Authors: Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski Journal: Am J Respir Crit Care Med Date: 2007-05-16 Impact factor: 21.405
Authors: Hao Wang; Richard D Robinson; Carlos Johnson; Nestor R Zenarosa; Rani D Jayswal; Joshua Keithley; Kathleen A Delaney Journal: BMC Cardiovasc Disord Date: 2014-08-07 Impact factor: 2.298